We describe a patient with recurrent relapses after allogeneic BMT for multiple myeloma who repeatedly went into CR after donor leukocyte infusions (DLI). The first bone marrow relapse, 24 months after allogeneic BMT, was treated successfully with the infusion of 1.2 ؋10 8 donor T cells. The second extramedullary relapse, 18 months later with a pleural mass and midthoracic spine process, responded again to DLI, however, only after three courses were given, each with escalating doses of T cells. The pleural mass was treated successfully with radiation therapy after the second DLI but reappeared 3 months later and responded again to the final DLI course with 5 ؋ 10 8 T cells/kg. Nevertheless, graft-versus-host disease (GVHD) did not occur. Retrospective analysis of minimal residual disease in bone marrow aspirates during CR periods using a sensitive quantitative tumor-specific PCR showed that BM tumor cell infiltration persisted. The possible clinical implications of this case report, like maintenance DLI and the aim for molecular remissions, are discussed. Keywords: multiple myeloma; BMT; donor leukocytes; GVHD A graft-versus-myeloma (GVM) effect achieved by the infusion of donor leukocytes, similar to the effect in CML/AML 1,2 , has recently been described in patients with progressive or relapsed multiple myeloma after allogeneic In a retrospective analysis of 13 patients, eight of 13 (62%) patients responded (including 30% CR), with a median response duration of 5 months. 4 The only prognostic factors for response were a T cell dose greater than 1 ϫ 10 8 per kg and the occurrence of GVHD. The results confirmed the favorable GVM effect of DLI reported earlier in single patients.
A graft-versus-myeloma (GVM) effect achieved by the infusion of donor leukocytes, similar to the effect in CML/AML 1,2 , has recently been described in patients with progressive or relapsed multiple myeloma after allogeneic BMT. [3] [4] [5] [6] In a retrospective analysis of 13 patients, eight of 13 (62%) patients responded (including 30% CR), with a median response duration of 5 months. 4 The only prognostic factors for response were a T cell dose greater than 1 ϫ 10 8 per kg and the occurrence of GVHD. The results confirmed the favorable GVM effect of DLI reported earlier in single patients. 3, 4 Here we present the first multiple myeloma patient with recurrent relapses after allogeneic BMT Correspondence: Dr H Lokhorst, University Hospital Utrecht, Department of Haematology (G03.647), PO Box 85.500, 3508 GA Utrecht, The Netherlands Received 13 July 1998; accepted 24 August 1998 who achieved CR repeatedly with DLI from the original BM donor.
Case report
A 49-year-old man received an allogeneic BMT for multiple myeloma (IgG/kappa, stage IIIA). He was in partial remission after previous chemotherapy with intermittent melphalan/prednisone courses and vincristine/doxorubicin/ dexamethasone (VAD). The donor was his HLA-identical 53-year-old brother. The conditioning regimen consisted of cyclophosphamide (60 mg/kg for 2 days) and total body irradiation (6 Gy on each of 2 successive days). The partly T cell-depleted marrow graft contained 1 ϫ 10 5 T cells per kg. T cell depletion was performed using soybean agglutinin and rosetting with 2-aminoethyl isothiouranimum bromide-treated sheep red blood cells. CsA for prevention of acute GVHD was started on day Ϫ2. Acute GVHD (grade II) developed on day ϩ17 and was treated with systemic prednisone (2 mg per kg/day orally). It merged into chronic GVHD (extensive disease), but after 18 months the immunosuppression could be stopped after GVHD had resolved completely. Analysis of chimerism from 6 months after BMT demonstrated that all peripheral blood T cells were of donor origin. The patient achieved a partial remission after allo-BMT with persistence of monoclonal plasma cells in the BM aspirate and a serum M protein.
However, 24 months after BMT, the serum M protein increased again to 16 g/l and the bone marrow was infiltrated with IgG kappa-positive plasma cells. He was treated with DLI from the original marrow donor that was performed for 3 successive days. The total dose of leukocytes infused was 4.2 ϫ 10 8 per kg, containing 1.2 ϫ 10 8 T cells per kg. GVHD of the skin and liver developed 36 days later and was successfully treated with prednisone, 1 mg/kg for 6 weeks. The relapsed multiple myeloma responded 10 weeks after DLI and disappeared completely after 4 months. Eighteen months after the second CR was achieved, the multiple myeloma relapsed again with an increasing M protein (up to 19 g/l), a pleural mass and a pathologic rib fracture. Bone marrow analysis failed to show monoclonal plasma cells. The patient was treated for the second time with DLI, now containing 1 ϫ 10 7 T cells per kg. Because of lack of response and absence of GVHD, the DLI was repeated 3 months later, with an escalating dose of 1 ϫ 10 8 T cells per kg. One month later, the patient was admitted with paraplegia due to a large process at the midthoracic spine with spinal cord compression and direct extension to the left-sided pleura. He was treated immediately with local radiation therapy (28 Gy in eight fractions), combined with dexamethasone 16 mg/day for 4 weeks after which dexamethasone dose was gradually tapered to zero. The pleural mass disappeared and the M protein decreased to 9 g/l. The motor weakness of the legs improved slowly, and after reevaluation he was able to walk small distances with a walking frame. The pleural mass and thoracic pain reappeared 3 months later accompanied by an increase in serum M protein to 17 g/l. Repeated bone marrow aspirates and biopsies again failed to show monoclonal plasma cells. Subsequently, the patient received DLI containing 5 ϫ 10 8 T cells/kg. Four months later, the pleural mass had disappeared completely and the serum M protein (as tested by immunofixation) and monocolonal marrow plasma cells were absent, indicative of the second CR. No GVHD has been observed to date. Now, 10 months after the latest DLI, the patient is still in remission, feeling quite well with still improving mobility, and without immunosuppressive therapy.
Retrospectively, bone marrow samples were analyzed with a patient-specific quantitative ASO-PCR as described before. 7, 8 This PCR has the sensitivity to detect 10 Ϫ4 to 10 Ϫ5 -10
Ϫ6
. The analysis revealed that during the CR periods after BMT and DLI and during the extramedullary relapse, myeloma cell infiltration persisted in the bone marrow ( Figure 1 ).
Discussion
Four observations can be made from this case report. The first one is that although the GVM effect of donor T cell infusion can be transient, recurrent relapses after DLI can respond again to subsequent DLI courses. To date, it is not known which tumor antigen nor which type of donor effector cells are involved in the GVM reaction. Although the association between the occurrence of GVHD and GVM suggests that minor histocompatibility antigens are involved, proof of this assumption is lacking. In vivo modulation of putative target antigens on myeloma cells or the induction of T cell tolerance may be responsible for the exhaustion of GVM. The complete response to the fourth DLI suggests that T cell tolerance might be responsible for tumor regrowth. A defect that was restored by the infusion of fresh donor T cells. However, identification of the effector cells and target antigens involved is needed to prove this hypothesis.
The second observation from this case report is that the definition of CR of multiple myeloma after allogeneic BMT or immunotherapy might be redefined. Although apparently in CR, the patient relapsed from persistent residual disease as shown by molecular analysis with a patient-specific ASO-PCR. 8 Molecular remission is rarely if ever achieved after single or double autografting. 9 After allogeneic BMT, a higher proportion (45% in a study by Corradini et al Our PCR analysis of patients after autologous and allo geneic stem cell transplantation confirms these results (manuscript in preparation). Although the clinical significance of the determination of minimal residual disease after intensive treatment needs to be determined, it is likely that cure will only occur in the group of patients in which myeloma cells are no longer detectable. Monitoring the results of allogeneic BMT and the effect and timing of immunotherapy may therefore need more sensitive methods to detect residual myeloma than the classical serum/urine and bone marrow investigations.
The third observation of the case report is the fact that DLI can be effective also against extramedullary relapses of MM. This phenomenon which appears rather frequently in end-stage disease and during relapse after BMT 5 has been earlier reported to be resistant to DLI. 10 The fourth observation is that dose escalation of DLI may be associated with less GVHD while the graft-versustumor effect is preserved, a phenomenon that we have observed in other patients as well. This may have important clinical implications for the development of T cell-based immunotherapies like non-myeloablative transplants (so called 'minitransplants') followed by donor T cell infusions. 11, 12 In conclusion, this case report supports the strategy of infusion of repeated courses of DLI in persistent or relapsed multiple myeloma, including extramedullary relapses after allogeneic BMT. Patients may be treated by escalating doses of donor T cells, until a true molecular CR has been achieved (or severe GVHD develops). Although response is often accompanied with GVHD, it can also occur without GVHD.
